Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.77 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.77 |
| ▸ | KIT | P10721 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.73 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.73 |
| ▸ | CIT | O14578 | 1/20 | 0.73 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | STK17B | O94768 | 1/20 | 0.73 |
| ▸ | STK10 | O94804 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | FYN | P06241 | 1/20 | 0.73 |
| ▸ | YES1 | P07947 | 1/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15772886 | 1.00 | EGFR (0.77) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL15781185 | 0.93 | EGFR (0.67) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL18595916 | 0.91 | EGFR (0.82) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL15772984 | 0.90 | EGFR (0.85) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL15772982 | 0.90 | EGFR (0.85) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL15781145 | 0.89 | EGFR (0.85) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL33143 | 0.87 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL14427862 | 0.87 | EGFR (0.95) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30115330 | 0.87 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30115367 | 0.87 | EGFR (0.90) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| EP-2716633-B1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| EP-2716633-B1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | EGFR 194/4885ERBB2 53/4885ERBB4 109/4885 |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | EGFR 194/4885ERBB2 53/4885ERBB4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.